Does dietary DHA improve neural function in children? Observations in phenylketonuria.
Children with phenylketonuria (PKU) have a restricted protein intake and thus low dietary intakes of long-chain polyunsaturated fatty acids (LC-PUFA), which may cause subtle neurological deficits. We measured plasma phospholipid fatty acids and visual evoked potential (VEP) in 36 children with well-controlled PKU (6.3+/-0.6 years, 19 girls), before and after 3 months of supplementing fish oil capsules providing 15 mg docosahexaenoic acid (DHA)/kg daily. The motometric Rostock-Oseretzky Scale (ROS) was performed before and after supplementation in the 24 PKU children aged >4 years. VEP latencies and ROS were also assessed in omnivorous, age-matched controls without fish oil supply at baseline and after 3 months. Fish oil supply increased plasma phospholipid eicosapentaenoic acid (EPA) (0.40+/-0.03 vs 3.31+/-0.19%, p<0.001) and DHA (2.37+/-0.10 vs 7.05+/-0.24%, p<0.001), but decreased arachidonic acid (AA) (9.26+/-0.23 vs 6.76+/-0.16%, p<0.001). Plasma phenylalanine was unchanged. VEP latencies and ROS results significantly improved after fish oil in PKU children, but remained unchanged in controls. The improvements of VEP latencies, fine motor and coordination skills indicate that preformed n-3 LC-PUFA are needed for neural normalcy in PKU children. The optimal type and dose of supply still needs to be determined. Since PKU children are generally healthy and have normal energy and fatty acid metabolism, these data lead us to conclude that childhood populations in general require preformed n-3 LC-PUFA to achieve optimal neurological function.
Koletzko
Berthold
B
Division of Metabolic Diseases and Nutritional Medicine, Dr. von Hauner Children's Hospital, University of Munich Medical Centre, Lindwurmstr. 4, 80337 Munich, Germany. office.koletzko@med.uni-muenchen.de
Beblo
Skadi
S
Demmelmair
Hans
H
Müller-Felber
Wolfgang
W
Hanebutt
Fabienne L
FL
D002648:Child; D002657:Child Development / Q000187:drug effects; D002675:Child, Preschool; D004281:Docosahexaenoic Acids / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism; D015118:Eicosapentaenoic Acid / Q000097:blood; D005074:Evoked Potentials, Visual / Q000187:drug effects; D005260:Female; D005395:Fish Oils / Q000008:administration & dosage* / Q000378:metabolism; D006801:Humans; D008297:Male; D009048:Motor Skills / Q000187:drug effects; D010661:Phenylketonurias / Q000097:blood / Q000178:diet therapy* / Q000503:physiopathology; D010743:Phospholipids / Q000097:blood
D005395:Fish Oils; D010743:Phospholipids; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid